Cover Image
市場調查報告書

POC (照護現場) 分子診斷的全球市場:各用途、各技術 (PCR/微陣列/混合化/遺傳基因定序基礎)、各檢驗場所、各領域的未來預測

Point of Care (PoC) Molecular Diagnostics Market Analysis By Application, By Technology (PCR-based, Microarray-based, Hybridization-based, Genetic Sequencing-based), By Test Location And Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 361251
出版日期 內容資訊 英文 83 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
POC (照護現場) 分子診斷的全球市場:各用途、各技術 (PCR/微陣列/混合化/遺傳基因定序基礎)、各檢驗場所、各領域的未來預測 Point of Care (PoC) Molecular Diagnostics Market Analysis By Application, By Technology (PCR-based, Microarray-based, Hybridization-based, Genetic Sequencing-based), By Test Location And Segment Forecasts To 2024
出版日期: 2016年06月01日 內容資訊: 英文 83 Pages
簡介

全球POC分子診斷的市場規模,2014年預計達到39億美元。由於近幾年的技術進步,檢驗所之外的地方 (藥局、體檢所、自己的家等)也能進行分子診斷,及產品、價格的選項擴大,開發中國家也可利用,具成本效率且迅速的檢驗方法的登場等,成為市場成長的主要原因。

本報告提供全球POC (照護現場) 分子診斷的相關市場相關分析,整體市場規模的變化、預測 (過去4年、今後7年份) ,及主要推動及阻礙市場要素,各用途、各技術、各檢驗場所、各最終用途、各地區的詳細趨勢,主要企業簡介、市場佔有率等調查評估。

第1章 分析方法、範圍

第2章 摘要整理

第3章 POC分子診斷產業的未來展望

  • 市場明細
  • 市場規模、成長率預測
    • 推動市場要素分析
    • 阻礙市場要素分析
  • POC (照護現場) 分子診斷市場動態
  • 重要度高的市場機會
  • 波特的五力分析
  • 主要企業分析
  • POC分子診斷市場PESTEL分析

第4章 POC分子診斷市場未來展望:各用途

  • 感染疾病
    • 市場規模的估計值、預測值 (以金額為準,總計12年份)
  • 腫瘤
  • 血液檢驗
  • 產前檢查
  • 內分泌檢查
  • 其他

第5章 POC分子診斷市場未來展望:各技術

  • PCR (聚合酵素鏈鎖反應) 基礎
  • 遺傳基因定序基礎
  • 混合化基礎
  • 微陣列基礎

第6章 POC分子診斷市場未來展望:各檢驗場所

  • OTC (Over-the-counter:一般藥)
  • POC (照護現場)

第7章 POC分子診斷市場:各最終用途未來展望

  • 診療所
  • 醫院
  • 自己的家治療
  • 醫療看護設施
  • 其他

第8章 POC分子診斷市場:各地區的未來展望

  • 北美
    • 美國市場
      • 各用途的市場規模 (以金額為準,總計12年份)
      • 各技術的市場規模 (以金額為準,總計12年份)
      • 各檢驗場所的市場規模 (以金額為準,總計12年份)
      • 各最終用途市場規模 (以金額為準,總計12年份)
    • 加拿大市場
  • 歐洲
    • 德國市場
    • 英國市場
  • 亞太地區
    • 日本市場
    • 中國市場
  • 南美
    • 巴西市場
  • 中東、非洲
    • 南非市場

第9章 競爭環境

  • Abbott Laboratories
    • 企業概要
    • 收益分析
    • 產品比較分析
    • 策略性配合措施
  • Alere Inc (Abbott)
  • Bayer Healthcare
  • Roche Diagnostics
  • Bio-rad Laboratories
  • Danaher Corporation
  • bioMerieux
  • Dako
  • Abaxis Inc.
  • OraSure Technologies Inc.

圖表一覽

目錄
Product Code: 978-1-68038-886-2

Global point of care molecular diagnostics market is anticipated to reach USD 3.9 billion by 2024, according to a new report by Grand View Research, Inc. Ongoing research & development to miniaturize molecular diagnostics testing that provides enhanced near patient testing with high accuracy & lesser turnaround times are major factors expected to reinforce the high growth potential for POC MDx products.

Growing demand for CLIA tests that are, by definition, portable and safe enough to be used in non-laboratory settings such as pharmacy clinics, physician offices, and home-care settings, is expected to drive demand in the market over the forecast period. Ongoing research and development is continually supported and funded by a number of major international entities including the national governments of developed countries and high-value private funding agencies such as the Bill & Melinda Gates Foundation.

Furthermore, a growing portfolio of point-of-care testing capabilities that, had initially been focused on screening, testing, and diagnosis of infectious diseases in low-income developing countries, has been developing at a rapid pace over the past decade to expand its potential market to a broader range of medical faculties. Consequently, POC and molecular diagnosis tests are available and/or are under development for cardiology monitoring, oncology testing, and hematology testing.

Recent advances in the development of microfluidics and genetic sequencing instrumentation pave the way for development of cost-effective, highly accurate and rapid testing platforms, which are able to be used as true POC systems. This is a key factor that significantly contributes towards the favorably funded, high growth potential environment prevalent in the point of care molecular diagnostics market.

Further key findings from the report suggest:

  • Application of POC MDx tests for infectious diseases accounted for over 45% of market revenue in 2015. The large share can be accounted for by the presence of an extensive portfolio of the concerned tests with a number of major market entities. Furthermore, growing disease burden of infectious diseases in developing as well as developed countries is another factor the reinforces the dominance of this segment.
  • PCR-based POC tests accounted for the largest share of the market in 2015. Widespread usage of PCR-based techniques for molecular diagnosis and commercialization of POC real time PCR products such as the cobas LIAT by Roche have provided this segment with ample opportunities for revenue generation and are expected to maintain a favorable market environment over the forecast period.
  • North America was observed to be the most lucrative region on this market and estimated to account for over 40% of the global revenue. presence of a technologically advanced medical framework, sophisticated insurance & copayment system & high R&D investment by governments and private funding organizations for the development of POC MDx tests are major factors responsible for the region's dominant market position.
  • Key players operating in this industry include Johnson & Johnson, Danaher Corp., Cepheid, Bio-Rad Laboratories, bioMerieux, Becton Dickinson, Roche Diagnostics, Bayer Healthcare, Alere Inc (Abbott), Abbott Laboratories among others.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2. Executive Summary

Chapter 3. Point of care Molecular Diagnostics Industry Outlook

  • 3.1. Market Segmentation
  • 3.2. Market Size and Growth Prospects
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Point of care Molecular Diagnostics Market Dynamics
  • 3.4. Key Opportunities Prioritized, 2015
  • 3.5. Industry Analysis -Porter's
  • 3.6. Point of care Molecular Diagnostics Market PESTEL Analysis

Chapter 4. Point of care Molecular Diagnostics Outlook, by Application

  • 4.1. Infectious Diseases
    • 4.1.1. Infectious Diseases Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 4.2. Oncology
    • 4.2.1. Oncology Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 4.3. Hematology
    • 4.3.1. Hematology Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 4.4. Prenatal Testing
    • 4.4.1. Prenatal Testing Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 4.5. Endocrinology
    • 4.5.1. Oncology Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 4.6. Other Applications
    • 4.6.1. Other Applications Market Estimates and Forecasts, 2013 - 2024 (USD Million)

Chapter 5. Point of care Molecular Diagnostics Outlook, by Technology

  • 5.1. PCR-based
    • 5.1.1. PCR-based Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 5.2. Genetic Sequencing-based
    • 5.2.1. Genetic Sequencing-based Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 5.3. Hybridization-based
    • 5.3.1. Hybridization-based Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 5.4. Microarray-based
    • 5.4.1. Microarray-based Market Estimates and Forecasts, 2013 - 2024 (USD Million)

Chapter 6. Point of care Molecular Diagnostics Outlook, by Test Location

  • 6.1. OTC (Over-the-counter)
    • 6.1.1. OTC Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 6.2. POC(Point-of-care)
    • 6.2.1. POC Market Estimates and Forecasts, 2013 - 2024 (USD Million)

Chapter 7. Point of care Molecular Diagnostics Outlook, By End-use

  • 7.1. Decentralized Labs
    • 7.1.1. Decentralized Labs Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 7.2. Hospitals
    • 7.2.1. Hospitals Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 7.3. Home-care
    • 7.3.1. Home-care Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 7.4. Assisted Living Healthcare Facilities
    • 7.4.1. Assisted Living Healthcare Facilities Market Estimates and Forecasts, 2013 - 2024 (USD Million)
  • 7.5. Other Uses
    • 7.5.1. Other Uses Market Estimates and Forecasts, 2013 - 2024 (USD Million)

Chapter 8. Point of care Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2013 - 2024)

  • 8.1. North America
    • 8.1.1. U.S.
      • 8.1.1.1. Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
      • 8.1.1.2. Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
      • 8.1.1.3. Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
      • 8.1.1.4. Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
    • 8.1.2. Canada
      • 8.1.2.1. Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
      • 8.1.2.2. Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
      • 8.1.2.3. Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
      • 8.1.2.4. Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 8.2. Europe
    • 8.2.1. Germany
      • 8.2.1.1. Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
      • 8.2.1.2. Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
      • 8.2.1.3. Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
      • 8.2.1.4. Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
    • 8.2.2. UK
      • 8.2.2.1. Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
      • 8.2.2.2. Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
      • 8.2.2.3. Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
      • 8.2.2.4. Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 8.3. Asia Pacific
    • 8.3.1. Japan
      • 8.3.1.1. Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
      • 8.3.1.2. Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
      • 8.3.1.3. Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
      • 8.3.1.4. Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
    • 8.3.2. China
      • 8.3.2.1. Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
      • 8.3.2.2. Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
      • 8.3.2.3. Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
      • 8.3.2.4. Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 8.4. Latin America
    • 8.4.1. Brazil
      • 8.4.1.1. Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
      • 8.4.1.2. Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
      • 8.4.1.3. Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
      • 8.4.1.4. Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 8.5. MEA
    • 8.5.1. South Africa
      • 8.5.1.1. Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
      • 8.5.1.2. Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
      • 8.5.1.3. Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
      • 8.5.1.4. Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Abbott Laboratories
    • 9.1.1. Company Overview
    • 9.1.2. Revenue Analysis
    • 9.1.3. Product Benchmarking
    • 9.1.4. Strategic Development
  • 9.2. Alere Inc (Abbott)
    • 9.2.1. Company Overview
    • 9.2.2. Revenue Analysis
    • 9.2.3. Product Benchmarking
    • 9.2.4. Strategic Development
  • 9.3. Bayer Healthcare
    • 9.3.1. Company Overview
    • 9.3.2. Revenue Analysis
    • 9.3.3. Product Benchmarking
    • 9.3.4. Strategic Development
  • 9.4. Roche Diagnostics
    • 9.4.1. Company Overview
    • 9.4.2. Revenue Analysis
    • 9.4.3. Product Benchmarking
    • 9.4.4. Strategic Development
  • 9.5. Bio-rad Laboratories
    • 9.5.1. Company Overview
    • 9.5.2. Revenue Analysis
    • 9.5.3. Product Benchmarking
    • 9.5.4. Strategic Development
  • 9.6. Danaher Corporation
    • 9.6.1. Company Overview
    • 9.6.2. Revenue Analysis
    • 9.6.3. Product Benchmarking
    • 9.6.4. Strategic Development
  • 9.7. bioMerieux
    • 9.7.1. Company Overview
    • 9.7.2. Revenue Analysis
    • 9.7.3. Product Benchmarking
    • 9.7.4. Strategic Development
  • 9.8. Dako
    • 9.8.1. Company Overview
    • 9.8.2. Revenue Analysis
    • 9.8.3. Product Benchmarking
    • 9.8.4. Strategic Development
  • 9.9. Abaxis Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Revenue Analysis
    • 9.9.3. Product Benchmarking
    • 9.9.4. Strategic Development
  • 9.10. OraSure Technologies Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Revenue Analysis
    • 9.10.3. Product Benchmarking
    • 9.10.4. Strategic Development

List of Tables

  • 1. Point of care Molecular Diagnostics market - Industry Snapshot & Key Buying Criteria, 2013 - 2024
  • 2. Global Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 3. Global Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 4. Global Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 5. Global Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 6. Global Point of care Molecular Diagnostics market, by region, 2013 - 2024 (USD Million)
  • 7. Point of care Molecular Diagnostics- Key market driver analysis
  • 8. Point of care Molecular Diagnostics- Key market restraint analysis
  • 9. North America Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 10. North America Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 11. North America Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 12. North America Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 13. U.S. Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 14. U.S. Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 15. U.S. Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 16. U.S. Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 17. Canada Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 18. Canada Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 19. Canada Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 20. Canada Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 21. Europe Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 22. Europe Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 23. Europe Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 24. Europe Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 25. Germany Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 26. Germany Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 27. Germany Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 28. Germany Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 29. UK Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 30. UK Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 31. UK Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 32. UK Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 33. Asia Pacific Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 34. Asia Pacific Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 35. Asia Pacific Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 36. Asia Pacific Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 37. Japan Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 38. Japan Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 39. Japan Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 40. Japan Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 41. China Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 42. China Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 43. China Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 44. China Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 45. Latin America Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 46. Latin America Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 47. Latin America Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 48. Latin America Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 49. Brazil Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 50. Brazil Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 51. Brazil Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 52. Brazil Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 53. MEA Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 54. MEA Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 55. MEA Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 56. MEA Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)
  • 57. South Africa Point of care Molecular Diagnostics market, by application, 2013 - 2024 (USD Million)
  • 58. South Africa Point of care Molecular Diagnostics market, by technology, 2013 - 2024 (USD Million)
  • 59. South Africa Point of care Molecular Diagnostics market, by test location, 2013 - 2024 (USD Million)
  • 60. South Africa Point of care Molecular Diagnostics market, by end-use, 2013 - 2024 (USD Million)

List of Figures

  • 1. Point of care Molecular Diagnostics market segmentation
  • 2. Global Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 3. Point of care Molecular Diagnostics market dynamics
  • 4. Key opportunities prioritized, 2015
  • 5. Point of care Molecular Diagnostics market - Porter's Analysis
  • 6. Point of care Molecular Diagnostics market - PESTEL analysis
  • 7. Point of care Molecular Diagnostics revenue share, by application, 2015 & 2022
  • 8. POC MDx Infectious Diseases market, 2013 - 2024 (USD Million)
  • 9. POC MDx Oncology market, 2013 - 2024 (USD Million)
  • 10. POC MDx Hematology market, 2013 - 2024 (USD Million)
  • 11. POC MDx Prenatal Testing market, 2013 - 2024 (USD Million)
  • 12. POC MDx Endocrinology market, 2013 - 2024 (USD Million)
  • 13. POC MDx Other Applications market, 2013 - 2024 (USD Million)
  • 14. Point of care Molecular Diagnostics revenue share, by technology, 2015 & 2022
  • 15. POC MDx PCR-based market, 2013 - 2024 (USD Million)
  • 16. POC MDx Genetic Sequencing-based market, 2013 - 2024 (USD Million)
  • 17. POC MDx Hybridization-based market, 2013 - 2024 (USD Million)
  • 18. POC MDx Microarray-based market, 2013 - 2024 (USD Million)
  • 19. Point of care Molecular Diagnostics revenue share, by test location, 2015 & 2022
  • 20. POC MDx over-the-counter market, 2013 - 2024 (USD Million)
  • 21. POC MDx Point of care market, 2013 - 2024 (USD Million)
  • 22. Point of care Molecular Diagnostics revenue share, by end-use, 2015 & 2022
  • 23. POC MDx Decentralized Labs market, 2013 - 2024 (USD Million)
  • 24. POC MDx Hospitals market, 2013 - 2024 (USD Million)
  • 25. POC MDx Home-care market, 2013 - 2024 (USD Million)
  • 26. POC MDx Assisted Living Healthcare Facilities market, 2013 - 2024 (USD Million)
  • 27. POC MDx Other uses market, 2013 - 2024 (USD Million)
  • 28. Point of care Molecular Diagnostics revenue share, by region, 2015 & 2022
  • 29. North America Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 30. U.S. Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 31. Canada Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 32. Europe Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 33. Germany Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 34. UK Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 35. Asia Pacific Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 36. Japan Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 37. China Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 38. Latin America Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 39. Brazil Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 40. MEA Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
  • 41. South Africa Point of care Molecular Diagnostics market, 2013 - 2024 (USD Million)
Back to Top